Anteris Announces Strategic Investment from Medtronic to Advance TAVR Technology with $320 Million in Combined Funding

Anteris Technologies has completed a $320 million capital raise, including a $90 million strategic investment from Medtronic. The investment supports the global pivotal PARADIGM trial and advances the commercialization of the DurAVR Transcatheter Heart Valve. Anteris and Medtronic aim to reshape the TAVR market through clinical science and valve design improvements, while maintaining standards for durability, hemodynamics, and long-term patient outcomes.